At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 28 target
Drug / intervention
Azacitidine +1 moredrug
Likely dose
Azacitidine 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Efficacy and Safety of Azacitidine in Combination With Chidamide in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma Unfit for Conventional Chemotherapy
In Brief
A Phase 2 clinical trial evaluating Azacitidine and Chidamide for Peripheral T-cell Lymphoma. Targeting 28 participants across 1 site.
Detailed Summary
This prospective, open-label, single-arm study will evaluate the efficacy and safety of azacitidine in combination with chidamide in treatment of newly diagnosed peripheral T-cell lymphoma unfit for conventional chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral T-cell Lymphoma
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
202120222023202420252026
Enrollment StartJun 2020
First PostedJul 2020
Primary CompletionJun 2022
Study CompletionJun 2024
TodayJul 2026
First PostedJul 21, 2020
Enrollment StartJun 20, 2020
Primary CompletionJun 20, 2022
Study CompletionJun 20, 2024
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 5.9 years ago
Interventions
Azacitidinedrug
100mg D1-7
Chidamidedrug
30mg BIW PO